Biomarkers Market Size, Share, Industry, Forecast and outlook (2023-2030)

Biomarkers Market is segmented By Product Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), By Application (Drug Discovery and Development, Diagnostics, Disease Risk Assessment, Personalized Medicine, Others), By Disease Indication (Cardiovascular Disorders, Cancer, Immunological Disorders, Neurological Disorders, Others), By Services (Biomarker Validation and Testing, Assay Development, Sample Preparation, Other Services), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Biomarkers Market Overview

Biomarkers Market size was valued USD YY million in 2021 and is estimated to reach USD YY million by 2029, growing at a CAGR of 12.5% during the forecast period (2023-2030).Biomarkers are used for the diagnosis health status of an individual. In medical terms, a measurable biomarker is a chemical component that reflects the presence as well as the severity of the disease.

Biomarkers Market Scope and Summary

To Get a Free Sample Click here

Biomarkers play a critical role in the early detection of diseases such as diabetes and cardiovascular disease, cancer, neurological disorders, immune disorders, and others. Every biomarker shows the presence of a disease or a state of health and can be used to provide a complete picture of a person's health and the need for diagnosis.

Biomarkers Market Dynamics and Trends

The biomarkers market growth is driven by the rising aging population and increasing incidence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders. In addition, increasing regulatory approval for biomarkers, rising demand in drug discovery, growing emphasis on personalized medicine and companion diagnostics are some of the other factors driving the growth of the biomarkers market globally.

Novel approaches and biomarker candidates for the early detection of ovarian cancer are expected to drive market growth.

Ovarian cancer (OC) is a disease that primarily affects postmenopausal women with stomach discomfort and bloating for several months before being diagnosed. Because the early stages of the disease are frequently asymptomatic, most people are diagnosed at advanced stages. According to Global Cancer Statistics, 2020, OC is the seventh most frequent cancer in women worldwide, accounting for around 314,000 new cases (3.4% of all new cancer cases in females) per year. Cancer Antigen-125 (CA-125) and transvaginal imaging are commonly used to diagnose ovarian cancer. The most commonly used serum biomarker is CA-125, although it lacks the sensitivity and specificity to be utilized alone as a screening test. It is also ineffective for early diagnosis since CA-125 expression levels are too low for accurate detection. There are several other illnesses where CA-125 levels increase, leading to false positive results, such as endometriosis, gall bladder disease, and liver cancer.

Similarly, transvaginal imaging is frequently ineffective at detecting small early-stage cancers. Therefore, several ways have been offered to address the inadequacies of present techniques. Studies on smaller molecules, such as circulating miRNA and cell-free DNA (cf-DNA), have recently received much attention. These compounds have emerged as prospective cancer biomarkers for non-invasive or minimally invasive diagnostic, prognostic, and therapeutic uses. Multiple miRNAs related to ovarian cancer, such as the Let-7 family miRNAs, and a range of miRNA assays, such as RT-qPCR, microarrays, and RNA sequencing, have been reported as promising screening tools. Moreover, 2021's online database miRCancer contained approximately 250 miRNAs related to ovarian malignancies. Depending on the cellular context, their up- or down-regulation was found relevant in disease development. Despite the outstanding analytical performance, a lack of reproducibility and the expensive costs involved with miRNA profiling indicate that their research is still ongoing. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

However, high investment costs, problems such as sample storage & collection, and unfavorable reimbursement scenarios are expected to hinder the market growth during the forecast period.

Industry Analysis

The biomarkers market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Biomarkers Market Segment Analysis

Efficacy biomarker segment is expected to hold the largest market share in the biomarkers market.

The efficacy biomarker segment accounted for the largest market share in 2021. The segment is further sub-segmented into Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate End Point Markers, and Predictive Biomarkers. The segment benefits because of its wide usage in oncology and antiretroviral treatments. This is coupled with numerous research on the identification of efficacy biomarkers. Moreover, the advancement of technology in sequence profiling tools, multiplex biomarkers platforms, and the growing requirement to analyze DNA sequences, proteins, and nucleic acids will boost the use of biomarkers in testing. Therefore, it has increased the demand for the efficacy biomarker. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Biomarkers Market Geographical Share

North American region is expected to hold the largest market share in the global biomarkers market.

North America accounted for the largest market share in 2021. Favorable healthcare infrastructure, the availability of technologically advanced products, rising investment in drug discovery, diagnostics, and a rising cancer patient pool will further stimulate the biomarkers market growth. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of biomarkers for cancer.

Moreover, many companies are interested in developing novel cancer detection tests or algorithms that use biomarkers. Amgen, for example, started its biomarker assist program in April 2021 to enable more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) to receive biomarker testing. Eligible patients can save money on biomarker testing through this program. Initiatives like this can help the category develop. In addition, the key players are adopting various key strategies such as product launches, mergers & acquisitions, and collaborations, contributing to the global biomarkers market growth. For instance, in April 2019, Synapse launched a new Innovative Medicines Initiative project, the Translational Safety Biomarker Pipeline (TransBioLine) Project, which aims to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular, and central nervous system) for application in drug development.

Biomarkers Companies and Competitive Landscape

Major key players in the biomarkers market are Bio-Rad Laboratories Inc., Merck Millipore, Qiagen N.V., Siemens Healthcare, Abbott Laboratories, Affymetrix Inc., (Thermo Fisher Scientific), Signosis, Inc., EKF Diagnostics Holdings, Inc., Biosims Technologies Sas, and Cisbio Bioassays.

Bio-Rad Laboratories Inc.:

Bio-Rad Laboratories, Inc. is an American company that continues to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process and medical diagnostic labs to obtain faster results. Bio-Rad’s life science products include instruments, software, consumables, reagents, and content for cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. Moreover, Bio-Rad’s diagnostic products and systems use various technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products support diagnosing, monitoring, and treating diseases and other medical conditions.

Product Portfolio: 

Bio-Plex Pro Human Cancer Biomarker: The Bio-Plex Pro human cancer biomarker panel 1, the 16-plex standard is used for generating standard curves and contains the following analytes:

• sEGFR
• FGF-basic
• Follistatin
• G-CSF
• HGF
• sHER-2/neu
• sIL-6Rα
• Leptin
• Osteopontin
• PECAM-1
• PDGF-AB/BB
• Prolactin
• SCF
• sTIE-2
• sVEGFR-1
• sVEGFR-2

The global biomarkers market report would provide an access to an approx. 45+market data table, 40+figures